Convergent Therapeutics has appointed Michael Rossi to its board of directors as the clinical-stage radiopharmaceutical company turns its focus towards new alpha-based radiotherapies.
Michael RossiConvergent Therapeutics
Rossi currently serves as CEO of Shine SPECT USA, a diagnostic radiopharmaceutical company, and previously served as president and CEO of Y-mAbs Therapeutics until its acquisition by SERB Pharmaceuticals in 2025. He has also held senior roles at Advanced Accelerator Applications, a Novartis company, Jubilant Radiopharma, and GE HealthCare. Rossi currently serves on the board of Nucleus RadioPharma.
Convergent is advancing its phase II study of CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted actinium-225 radioantibody in patients with metastatic castration-resistant prostate cancer.
